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General procedure for 2-step flow synthesis 
H-Cube
10 % Pd/C











0.1 M in EtOH (25 mL)






Benzyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate (2.5 mmol) was dissolved in EtOH (25 mL). 
The solution was pumped at a flow rate of 0.50 mL/min through an H-Cube (catalyst: 10 % Pd/C 
30x4 mm cartridge, full H2 mode, 25oC). Isocyanate (1.0 mmol) was dissolved in DMF (10 mL) 
and pumped via a second pump (0.50 mL/min) to mix with the intermediate from the H-Cube. The 
mixture continued through a stainless steel coiled reactor (2 mL, rt). The product was collected, 
diluted with water (20 mL), extracted with EtOAc (3x15 mL), dried over MgSO4 and filtered. The 
solvent was evaporated under reduced pressure.  


























0.05 M in DMF (10 mL)
O
Br








Cbz-protected diamine (0.50 mmol) and isocyanate (0.50 mmol) were dissolved in DMF (10.0 mL) 
in a pre-dried flask under argon. The solution was pumped at a flow rate of 0.20 mL/min through a 
coiled reactor (PFA, 5 mL, 100oC) followed by an H-Cube (catalyst: 10 % Pd/C 30x4 mm cartridge, 
full H2 mode, 80oC). The product was collected in a flask (5 mL) to release excess H2 and from 
there passed on via second pump (0.20 mL/min). Alkylating agent (1.5 mmol) was dissolved in 
DMF (30 mL) and pumped via a third pump (0.20 mL/min, started 40 min after the first pump) to 
mix with the intermediate from the second pump. The mixture continued through a glass column 
filled with Na2CO3/sand (9+9 g, 5 mL, 75oC). The solution was collected, the solvent evaporated 
under reduced pressure and the product purified by column chromatography using a semi-automatic 
Combiflash system (24 g silica, eluent gradient: Heptane/EtOAc) 
General procedure for improved 3-step flow synthesis (Configuration II) 
H-Cube
10 % Pd/C

















0.05 M in DMF (10 mL)














Cbz-protected diamine (0.50 mmol) and alkylating agent 0.50 mmol) were dissolved in DMF (10.0 
mL). The solution was pumped at a flow rate of 0.20 mL/min through a glass column filled with 
Na2CO3/sand (9+9 g, 5 mL, 75oC) followed by an H-Cube (catalyst: 10 % Pd/C 30x4 mm cartridge, 
full H2 mode, 80oC). The product was collected in a flask (5 mL) to release excess H2 and from 
there passed on via second pump (0.20 mL/min). Isocyanate (1.5 mmol) was dissolved in DMF (30 
mL) and pumped via a third pump (0.20 mL/min, started 40 min after the first pump) to mix with 
the intermediate from the second pump. The mixture continued through a coiled reactor (PFA, 5 
mL, 100oC). The solution was collected, the solvent evaporated under reduced pressure and the 
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product purified by column chromatography using a semi-automatic Combiflash system (24 g 











N-(tert-Butyl)-4-(3-phenoxybenzyl)piperazine-1-carboxamide (5) was prepared according to 
general procedure (Configuration I) from benzyl piperazine-1-carboxylate (108.9 mg, 0.494 mmol), 
tert-butyl isocyanate(49.3 mg, 0.497 mmol) and 1-(bromomethyl)-3-phenoxybenzene (397.7 mg, 
1.51 mmol) to afford the title compound (116.2 mg, 64%): 1H NMR (500 MHz, CDCl3) δ 7.33 (t, J 
= 7.9 Hz, 2H), 7.27 (t, J = 7.9 Hz, 1H), 7.09 (t, J = 7.4 Hz, 1H), 7.06 (d, J = 7.6 Hz, 1H), 7.04–6.98 
(m, 3H), 6.89 (dd, J = 8.0, 1.6 Hz, 1H), 4.36 (s, 1H), 3.49 (s, 2H), 3.35–3.28 (m, 4H), 2.46–2.37 (m, 
4H), 1.35 (s, 9H) ppm; 13C NMR (126 MHz, CDCl3) δ 157.23, 157.20, 157.01, 140.05, 129.71, 
129.52, 123.86, 123.18, 119.39, 118.76, 117.54, 62.50, 52.68, 50.68, 43.76, 29.46 ppm; HRMS 








4-(3-Cyanobenzyl)-N-(3,5-dimethylphenyl)piperazine-1-carboxamide (6) was prepared 
according to general procedure (Configuration I) from benzyl piperazine-1-carboxylate (110.4 mg, 
0.501 mmol), 1-isocyanato-3,5-dimethylbenzene (73.8 mg, 0.501 mmol) and 3-
(bromomethyl)benzonitrile (294.1 mg, 1.50 mmol) to afford the title compound (156.6 mg, 90%): 
1H NMR (500 MHz, CDCl3) δ 7.65 (s, 1H), 7.56 (t, J = 7.7 Hz, 2H), 7.43 (t, J = 7.7 Hz, 1H), 6.98 
(s, 2H), 6.66 (s, 1H), 6.54 (s, 1H), 3.53 (s, 2H), 3.51–3.45 (m, 4H), 2.46–2.40 (m, 4H), 2.25 (s, 6H) 
ppm; 13C NMR (126 MHz, CDCl3) δ 155.24, 139.71, 138.91, 138.47, 133.40, 132.38, 131.04, 
129.25, 124.93, 118.97, 117.99, 112.49, 61.96, 52.77, 44.12, 21.43 ppm; HRMS calcd. for 








4-(3-Phenoxy-benzyl)-piperazine-1-carboxylic acid 2-chloro-benzylamide (15) was prepared 
according to the general procedure for the 2-step flow synthesis using 2-chlorobenzylisocyanate 
(126.1 mg, 1.01 mmol) to afford the title compound: 1H NMR (600 MHz, CDCl3) δ 7.37 (d, J = 7.4 
Hz, 1H), 7.33–7.28 (m, 3H), 7.26 (t, J = 7.8 Hz, 1H), 7.21–7.14 (m, 2H), 7.08 (t, J = 7.4 Hz, 1H), 
7.04 (d, J = 7.6 Hz, 1H), 7.01–6.97 (m, J = 6.3, 5.3 Hz, 3H), 6.88 (dd, J = 8.1, 2.4 Hz, 1H), 5.40 (s, 
1H), 4.46 (d, J = 5.8 Hz, 2H), 3.47 (s, 2H), 3.39–3.35 (m, 4H), 2.42–2.36 (m, 4H) ppm; 13C NMR 
(151 MHz, CDCl3) δ 157.56, 157.22, 157.15, 139.93, 136.95, 133.27, 129.80, 129.72, 129.52, 
129.27, 128.44, 126.95, 123.87, 123.19, 119.38, 118.75, 117.53, 77.37, 77.16, 76.95, 62.46, 52.60, 











4-(3-Phenoxy-benzyl)-piperazine-1-carboxylic acid phenethyl-amide (16) was prepared 
according to the general procedure for the 2-step flow synthesis using (2-isocyanatoethyl)-benzene 
(150.2 mg, 1.02 mmol) to afford the title compound: 1H NMR (600 MHz, CDCl3) δ 7.35–7.25 (m, J 
= 30.8, 15.8, 7.7 Hz, 5H), 7.23–7.17 (m, J = 18.4, 7.6 Hz, 3H), 7.10 (t, J = 7.0 Hz, 1H), 7.05 (d, J = 
7.6 Hz, 1H), 7.02–6.98 (m, J = 8.7 Hz, 3H), 6.89 (dd, J = 8.1, 2.4 Hz, 1H), 4.67 (s, 1H), 3.48 (s, 
2H), 3.48–3.45 (m, 2H), 3.33–3.29 (m, 4H), 2.81 (t, J = 7.0 Hz, 2H), 2.41–2.37 (m, 4H) ppm; 13C 
NMR (151 MHz, CDCl3) δ 157.66, 157.28, 157.21, 140.00, 139.49, 129.77, 129.58, 128.89, 128.57, 
126.36, 123.91, 123.25, 119.45, 118.81, 117.59, 77.37, 77.16, 76.95, 62.55, 52.66, 43.67, 42.11, 








4-(3-Phenoxy-benzyl)-piperazine-1-carboxylic acid isopropylamide (17) was prepared according 
to the general procedure for the 2-step flow synthesis using isopropylisocyanate (126.1 mg, 1.01 
mmol) to afford the title compound: 1H NMR (600 MHz, CDCl3) δ 7.34 (t, J = 7.9 Hz, 2H), 7.30–
7.26 (m, J = 9.1, 6.6 Hz, 1H), 7.11 (t, J = 7.2 Hz, 1H), 7.07 (d, J = 7.6 Hz, 1H), 7.04–7.00 (m, 3H), 
6.90 (dd, J = 8.1, 2.2 Hz, 1H), 4.27 (s, 1H), 3.98 (dq, J = 13.4, 6.6 Hz, 4H), 3.50 (s, 2H), 3.37–3.32 
(m, 4H), 2.45–2.40 (m, 4H), 1.16 (d, J = 6.5 Hz, 6H) ppm; 13C NMR (151 MHz, CDCl3) δ 157.34, 
157.29, 157.19, 140.07, 129.82, 129.63, 123.98, 123.30, 119.52, 118.87, 117.67, 77.37, 77.16, 









4-(3-Phenoxy-benzyl)-piperazine-1-carboxylic acid cyclohexylamide (18) was prepared 
according to the general procedure for the 2-step flow synthesis using cyclohexaneisocyanate 
(126.1 mg, 1.01 mmol) to afford the title compound: 1H NMR (600 MHz, CDCl3) δ 7.29–7.23 (m, 
2H), 7.19 (t, J = 7.8 Hz, 1H), 7.05–7.00 (m, J = 7.4 Hz, 1H), 6.98 (d, J = 7.5 Hz, 1H), 6.96–6.89 (m, 
J = 7.8, 6.9 Hz, 3H), 6.83–6.78 (m, 1H), 4.54 (d, J = 7.3 Hz, 1H), 3.59–3.50 (m, 1H), 3.41 (s, 2H), 
3.30–3.24 (m, 4H), 2.37–2.31 (m, 4H), 1.89–1.81 (m, 2H), 1.67–1.58 (m, J = 10.1, 3.4 Hz, 2H), 
1.57–1.49 (m, 1H), 1.34–1.21 (m, J = 12.5 Hz, 2H), 1.10–0.97 (m, 3H) ppm; 13C NMR (151 MHz, 
CDCl3) δ 157.09, 157.06, 140.00, 129.62, 129.41, 123.78, 123.08, 119.27, 118.63, 117.40, 77.37, 
77.16, 76.95, 62.43, 52.59, 49.34, 43.60, 33.79, 25.57, 25.05 ppm; HRMS calcd. for C24H32N3O2 







4-(3-Phenoxy-benzyl)-piperazine-1-carboxylic acid benzylamide (19) was prepared according to 
general procedure (Configuration I) from benzyl piperazine-1-carboxylate (110.1 mg, 0.500 mmol), 
benzyl isocyanate (68.8 mg, 0.517 mmol) and 1-(bromomethyl)-3-phenoxybenzene (397.5 mg, 
1.511 mmol) to afford the title compound (188.3 mg, 94%): 1H NMR (600 MHz, CDCl3) δ 7.32–
7.28 (m, 2H), 7.26 (d, J = 6.9 Hz, 2H), 7.22–7.19 (m, 1H), 7.07 (tt, J = 7.6, 1.1 Hz, 1H), 7.03 (d, J = 
7.7 Hz, 1H), 7.01–6.99 (m, 1H), 6.99–6.96 (m, J = 4.5, 3.3, 1.8 Hz, 2H), 6.87 (ddd, J = 8.1, 2.5, 0.8 
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Hz, 1H), 5.16 (t, J = 5.6 Hz, 1H), 4.35 (d, J = 5.6 Hz, 2H), 3.44 (s, 2H), 3.37–3.29 (m, 4H), 2.39–
2.31 (m, 4H) ppm; 13C NMR (151 MHz, CDCl3) δ 157.67, 157.22, 157.15, 139.98, 139.61, 129.72, 
129.53, 128.49, 127.55, 127.12, 123.84, 123.20, 119.37, 118.76, 117.53, 62.47, 52.62, 44.75, 43.73 






4-(3-Phenoxy-benzyl)-[1,4]diazepane-1-carboxylic acid benzylamide (20) was prepared 
according to general procedure (Configuration I) from benzyl 1-homopiperazine carboxylate (117.2 
mg, 0.500 mmol), benzyl isocyanate (69.1 mg, 0.519 mmol) and 1-(bromomethyl)-3-
phenoxybenzene (394.9 mg, 1.501 mmol) to afford the title compound (102.5 mg, 49 %): 1H NMR 
(600 MHz, CDCl3) δ 7.33–7.27 (m, 7H), 7.25–7.22 (m, 2H), 7.09–7.06 (m, J = 8.5, 2.1, 1.1 Hz, 
1H), 7.05 (d, J = 7.6 Hz, 1H), 7.03–7.01 (m, 1H), 7.00–6.97 (m, 2H), 6.89–6.86 (m, 1H), 4.76 (t, J 
= 5.4 Hz, 1H), 4.41 (d, J = 5.5 Hz, 2H), 3.59 (s, 2H), 3.52 (s, 2H), 3.44 (t, J = 6.0 Hz, 2H), 2.68–
2.63 (m, 2H), 2.63–2.58 (m, 2H), 1.88–1.79 (m, 2H) ppm; 13C NMR (151 MHz, CDCl3) δ 157.51, 
157.24, 157.18, 140.93, 136.82, 136.56, 129.73, 129.51, 129.23, 127.75, 123.76, 123.17, 119.37, 
118.71, 117.38, 57.58, 54.87, 50.36, 44.64, 43.93, 40.90, 21.11, 15.76 ppm; HRMS calcd. for 







4-(3-Phenoxy-benzyl)-piperazine-1-carboxylic acid 4-methyl-benzylamide (21) was prepared 
according to general procedure (Configuration I) from benzyl piperazine-1-carboxylate (111.3 mg, 
0.505 mmol), 4-methylbenzyl isocyanate (73.9 mg, 0.502 mmol) and 1-(bromomethyl)-3-
phenoxybenzene (397.9 mg, 1.512 mmol) to afford the title compound (177.4 mg, 85%): 1H NMR 
(600 MHz, CDCl3) δ 7.37–7.32 (m, 2H), 7.29 (t, J = 7.8 Hz, 1H), 7.19 (d, J = 8.1 Hz, 2H), 7.14–
7.10 (m, 3H), 7.07 (d, J = 7.6 Hz, 1H), 7.05–7.03 (m, 1H), 7.03–7.00 (m, 2H), 6.93–6.90 (m, 1H), 
5.15 (t, J = 5.5 Hz, 1H), 4.35 (d, J = 5.5 Hz, 2H), 3.48 (s, 2H), 3.40–3.33 (m, 4H), 2.43–2.36 (m, 
4H), 2.33 (s, 3H) ppm; 13C NMR (151 MHz, CDCl3) δ 157.64, 157.20, 157.13, 139.95, 136.67, 
136.54, 129.70, 129.51, 129.14, 127.62, 123.82, 123.18, 119.34, 118.74, 117.51, 62.45, 52.60, 









4-(3-(2-Fluorophenoxy)benzyl)-N-(4-methylbenzyl)piperazine-1-carboxamide (22) was 
prepared according to general procedure (Configuration I) from benzyl piperazine-1-carboxylate 
(109.4 mg, 0.497 mmol), 4-methylbenzyl isocyanate (73.6 mg, 0.500 mmol) and 1-(3-
(bromomethyl)phenoxy)-2-fluorobenzene (421.3 mg, 1.50 mmol) to afford the title compound 
(198.0 mg, 92%): 1H NMR (500 MHz, CDCl3) δ 7.28 (t, J = 7.9 Hz, 1H), 7.23–7.17 (m, 3H), 7.17–
7.11 (m, J = 11.9, 4.9 Hz, 4H), 7.10–7.05 (m, J = 13.0, 5.0 Hz, 2H), 7.02 (s, 1H), 6.88 (dd, J = 8.1, 
2.0 Hz, 1H), 4.99 (t, J = 5.3 Hz, 1H), 4.38 (d, J = 5.4 Hz, 2H), 3.50 (s, 2H), 3.42–3.36 (m, 4H), 
2.47–2.39 (m, 4H), 2.35 (s, 3H) ppm; 13C NMR (126 MHz, CDCl3) δ 157.67 (s), 157.47 (s), 154.35 
(d, J = 248.6 Hz), 143.72 (d, J = 11.3 Hz), 140.02 (s,), 136.85 (s), 136.53 (s), 129.54 (s), 129.25 (s), 
127.76 (s), 124.83 (d, J = 6.9 Hz), 124.72 (d, J = 3.6 Hz), 123.76 (s), 121.85 (s), 117.82 (s), 117.09 
(d, J = 18.2 Hz), 115.96 (s), 62.48 (s), 52.66 (s), 44.69 (s), 43.78 (s), 21.11 (s) ppm; HRMS calcd. 









(S)-3-Methyl-4-(3-phenoxy-benzyl)-piperazine-1-carboxylic acid 4-methyl-benzylamide (23) 
was prepared according to general procedure (Configuration I) from (S)-benzyl 2-methylpiperazine-
1-carboxylate (115.0 mg, 0.491 mmol), 4-methylbenzyl isocyanate (73.4 mg, 0.499 mmol) and 1-
(bromomethyl)-3-phenoxybenzene (395.4 mg, 1.503 mmol) to afford the title compound (131.1 mg, 
62%): 1H NMR (600 MHz, CDCl3) δ 7.36–7.31 (m, 2H), 7.27 (t, J = 7.8 Hz, 1H), 7.19 (d, J = 8.1 
Hz, 2H), 7.14–7.08 (m, 3H), 7.07 (d, J = 7.6 Hz, 1H), 7.05–7.03 (m, 1H), 7.02–6.99 (m, 2H), 6.90–
6.87 (m, 1H), 4.97 (t, J = 5.4 Hz, 1H), 4.35 (dd, J = 5.4, 1.3 Hz, 2H), 3.98 (d, J = 13.6 Hz, 1H), 
3.68–3.61 (m, 1H), 3.55 (d, J = 12.5 Hz, 1H), 3.17 (d, J = 13.6 Hz, 1H), 3.06 (ddd, J = 12.8, 10.0, 
3.1 Hz, 1H), 2.83 (dd, J = 12.7, 8.9 Hz, 1H), 2.68 (dt, J = 7.2, 3.4 Hz, 1H), 2.44 (dqd, J = 9.4, 6.2, 
3.3 Hz, 1H), 2.33 (s, 3H), 2.11 (ddd, J = 11.6, 10.1, 3.3 Hz, 1H), 1.11 (d, J = 6.2 Hz, 3H) ppm; 13C 
NMR (151 MHz, CDCl3) δ 157.51, 157.24, 157.18, 140.93, 136.82, 136.56, 129.73, 129.51, 129.23, 
127.75, 123.76, 123.17, 119.37, 118.71, 117.38, 57.58, 54.87, 50.36, 44.64, 43.93, 40.90, 21.11, 










benzylamide (24) was prepared according to general procedure (Configuration I) from (R)-benzyl 
2-methylpiperazine-1-carboxylate (116.6 mg, 0.498 mmol), 4-methylbenzyl isocyanate (73.6 mg, 
0.500 mmol) and 4-(bromomethyl)-1-fluoro-2-phenoxybenzene (422.9 mg, 1.504 mmol) to afford 
the title compound (193.6 mg, 87 %): 1H NMR (600 MHz, CDCl3) δ 7.34–7.30 (m, 2H), 7.18 (d, J 
= 8.1 Hz, 2H), 7.14–7.06 (m, 6H), 6.98–6.95 (m, 2H), 4.97 (t, J = 5.4 Hz, 1H), 4.39–4.31 (m, 2H), 
3.92 (d, J = 13.6 Hz, 1H), 3.63 (ddd, J = 12.6, 2.9, 1.3 Hz, 1H), 3.54 (d, J = 12.6 Hz, 1H), 3.11 (d, J 
= 13.6 Hz, 1H), 3.05 (ddd, J = 12.8, 9.9, 3.1 Hz, 1H), 2.82 (dd, J = 12.7, 8.8 Hz, 1H), 2.63 (dt, J = 
7.3, 3.3 Hz, 1H), 2.42 (dqd, J = 9.4, 6.2, 3.3 Hz, 1H), 2.33 (s, 3H), 2.08 (ddd, J = 11.6, 9.9, 3.3 Hz, 
1H), 1.08 (d, J = 6.3 Hz, 3H) ppm; 13C NMR (151 MHz, CDCl3) δ 157.55 (s), 157.53 (s), 153.40 (d, 
J = 247.9 Hz), 143.22 (d, J = 11.7 Hz), 136.88 (s), 136.59 (s), 135.85 (d, J = 3.5 Hz), 129.75 (s), 
129.28 (s), 127.79 (s), 125.05 (d, J = 6.7 Hz), 123.06 (s), 122.34 (s), 117.00 (s), 116.76 (d, J = 18.3 
Hz), 57.05 (s), 54.90 (s), 50.38 (s), 50.22 (s), 44.70 (s), 43.96 (s), 21.15 (s), 15.69 (s) ppm; HRMS 








N-(4-Methylbenzyl)-4-(3-phenoxybenzyl)-2-phenylpiperazine-1-carboxamide (25) was 
prepared according to general procedure (Configuration I) from benzyl 3-phenylpiperazine-1-
carboxylate (145.5 mg, 0.491 mmol), 4-methylbenzyl isocyanate (74.3 mg, 0.505 mmol) and 1-
(bromomethyl)-3-phenoxybenzene (393.3 mg, 1.50 mmol) to afford the title compound (159.2 mg, 
66%): 1H NMR (500 MHz, CDCl3) δ 7.34–7.28 (m, J = 8.0 Hz, 4H), 7.26–7.19 (m, J = 9.1, 6.2 Hz, 
4H), 7.11–7.05 (m, 5H), 6.97 (d, J = 8.1 Hz, 3H), 6.93 (s, 1H), 6.87 (dd, J = 8.1, 1.5 Hz, 1H), 5.10 
(s, 1H), 4.82 (t, J = 5.3 Hz, 1H), 4.34 (d, J = 5.4 Hz, 2H), 3.73 (d, J = 13.0 Hz, 1H), 3.51 (d, J = 
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13.3 Hz, 1H), 3.38 (d, J = 13.3 Hz, 1H), 3.25–3.14 (m, 2H), 2.76 (d, J = 10.9 Hz, 1H), 2.43 (dd, J = 
11.7, 4.1 Hz, 1H), 2.30 (s, 3H), 2.20 (td, J = 11.4, 3.4 Hz, 1H) ppm; 13C NMR (126 MHz, CDCl3) δ 
158.09, 157.68, 140.53, 140.45, 137.25, 136.85, 130.20, 129.94, 129.66, 128.85, 128.05, 127.85, 
127.42, 124.29, 123.64, 119.82, 119.21, 118.16, 63.02, 56.21, 54.23, 53.56, 45.19, 40.96, 21.55 








N-(4-Methylbenzyl)-4-(3-phenoxybenzyl)-3-phenylpiperazine-1-carboxamide (26) was 
prepared according to general procedure (Configuration I) from benzyl 2-phenylpiperazine-1-
carboxylate (148.2 mg, 0.500 mmol), 4-methylbenzyl isocyanate (75.7 mg, 0.514 mmol) and 1-
(bromomethyl)-3-phenoxybenzene (398.2 mg, 1.51 mmol) to afford the title compound (140.5 mg, 
57%): 1H NMR (500 MHz, CDCl3) δ 7.41 (d, J = 7.3 Hz, 2H), 7.32 (dd, J = 15.0, 7.1 Hz, 4H), 7.27 
(d, J = 7.2 Hz, 1H), 7.22 (t, J = 7.8 Hz, 1H), 7.18 (d, J = 7.9 Hz, 2H), 7.14–7.08 (m, 3H), 6.99 (d, J 
= 8.0 Hz, 3H), 6.95 (s, 1H), 6.84 (dd, J = 8.1, 2.0 Hz, 1H), 4.70 (t, J = 5.2 Hz, 1H), 4.35 (d, J = 5.3 
Hz, 1H), 3.86 (dd, J = 12.7, 1.7 Hz, 1H), 3.76 (dd, J = 13.1, 4.1 Hz, 1H), 3.26 (dd, J = 10.5, 3.0 Hz, 
1H), 2.99 (td, J = 12.5, 2.3 Hz, 1H), 2.92–2.80 (m, 2H), 2.32 (s, 2H), 2.12 (td, J = 11.8, 2.9 Hz, 1H) 
ppm; 13C NMR (126 MHz, CDCl3) δ 157.37, 157.27, 140.89, 140.73, 137.13, 136.40, 129.84, 
129.54, 129.41, 128.88, 128.03, 127.98, 123.58, 123.35, 119.09, 118.97, 117.33, 66.97, 58.61, 












was prepared according to the general procedure (Configuration I) from (S)-benzyl 2-methyl-
piperazine-1-carboxylate (115.9 mg, 0.495 mmol), isocyanatocyclopentane (60.3 mg, 0.542 mmol) 
and 1-(3-(bromomethyl)phenoxy)-3,5-dichlorobenzene (486.8 mg, 1.47 mmol) to afford the title 
compound (142.0 mg, 62%): 1H NMR (500 MHz, CDCl3) δ 7.32 (t, J = 7.8 Hz, 1H), 7.15 (d, J = 7.6 
Hz, 1H), 7.06 (dd, J = 4.4, 2.7 Hz, 2H), 6.91 (dd, J = 8.1, 1.9 Hz, 1H), 6.85 (d, J = 1.6 Hz, 2H), 4.34 
(d, J = 6.7 Hz, 1H), 4.09 (h, J = 6.9 Hz, 1H), 4.00 (d, J = 13.7 Hz, 1H), 3.61 (dd, J = 12.6, 1.4 Hz, 
1H), 3.51 (d, J = 12.6 Hz, 1H), 3.20 (d, J = 13.7 Hz, 1H), 3.09–3.01 (m, 1H), 2.81 (dd, J = 12.6, 8.9 
Hz, 1H), 2.68 (dt, J = 11.5, 3.5 Hz, 1H), 2.50–2.42 (m, 1H), 2.13 (td, J = 11.6, 3.2 Hz, 1H), 1.99 
(td, J = 11.9, 6.4 Hz, 2H), 1.71–1.62 (m, 2H), 1.61–1.54 (m, 2H), 1.33 (td, J = 13.4, 6.9 Hz, 2H), 
1.12 (d, J = 6.2 Hz, 3H) ppm; 13C NMR (126 MHz, CDCl3) δ 159.12, 157.48, 155.56, 141.74, 
135.66, 130.00, 125.26, 123.07, 120.25, 118.48, 116.78, 57.63, 55.07, 52.64, 50.51, 50.47, 44.01, 









was prepared according to general procedure (Configuration I) from benzyl piperazine-1-
carboxylate (109.6 mg, 0.497 mmol), 1-isocyanato-1,2,3,4-tetrahydronaphthalene (87.5 mg, 0.505 
mmol) and 1-(bromomethyl)-3-phenoxybenzene  (393.9 mg, 1.50 mmol) to afford the title 
8 
 
compound (185.6 mg, 84%): 1H NMR (500 MHz, CDCl3) δ 7.36 (t, J = 7.2 Hz, 3H), 7.30 (dd, J = 
13.1, 5.1 Hz, 1H), 7.21–7.16 (m, 2H), 7.12 (dt, J = 11.2, 7.3 Hz, 3H), 7.08–7.01 (m, 3H), 6.93 (d, J 
= 8.1 Hz, 1H), 5.15–5.08 (m, J = 6.6 Hz, 1H), 4.81 (d, J = 8.0 Hz, 1H), 3.53 (s, 2H), 3.43–3.32 (m, 
4H), 2.89–2.72 (m, 2H), 2.46 (t, J = 4.7 Hz, 4H), 2.08 (dd, J = 12.8, 8.3 Hz, 1H), 1.85 (d, J = 4.7 
Hz, 3H) ppm; 13C NMR (126 MHz, CDCl3) δ 157.23, 157.20, 157.01, 140.05, 129.71, 129.52, 
123.86, 123.18, 119.39, 118.76, 117.54, 62.50, 52.68, 50.68, 43.76, 29.46 ppm; HRMS calcd. for 











was prepared according to general procedure (Configuration II) from (R)-benzyl 2-
methylpiperazine-1-carboxylate (116.5 mg, 0.497 mmol), 4-(bromomethyl)-1-fluoro-2-
phenoxybenzene (149.7 mg, 0.533 mmol) and 4-chlorobenzyl isocyanate (258.9 mg, 1.55 mmol) to 
afford the title compound (184.0 mg, 79%): 1H NMR (500 MHz, DMSO) δ 7.35–7.29 (m, 5H), 7.22 
(t, J = 7.7 Hz, 3H), 7.12–7.04 (m, 3H), 6.99 (t, J = 5.7 Hz, 1H), 6.95 (d, J = 8.3 Hz, 2H), 4.23–4.11 
(m, 1H), 4.05 (s, 1H), 3.65 (d, J = 12.7 Hz, 1H), 3.47 (d, J = 13.7 Hz, 1H), 3.28 (d, J = 13.7 Hz, 
1H), 2.93–2.84 (m, 1H), 2.70 (d, J = 10.3 Hz, 1H), 2.47 (s, 1H), 1.96 (dd, J = 11.0, 3.3 Hz, 1H), 
1.88 (td, J = 11.5, 2.8 Hz, 1H), 1.01 (d, J = 6.5 Hz, 1H) ppm; 13C NMR (126 MHz, DMSO) δ 
158.90 (s), 157.75 (d, J = 46.9 Hz), 153.21 (d, J = 245.5 Hz), 143.71 (d, J = 11.9 Hz), 141.08 (s), 
140.87 (s, J = 26.8 Hz), 136.74 (d, J = 2.4 Hz), 131.84 (d, J = 19.9 Hz), 130.90 (s), 129.69 (s), 
128.93 (d, J = 14.2 Hz), 125.72 (s, J = 6.6 Hz), 124.29 (s), 121.97 (s), 118.07 (s), 117.62 (d, J = 
18.2 Hz), 61.41 (s), 57.63 (s), 53.72 (s), 46.97 (s), 43.70 (s), 43.17 (s), 16.08 (s) ppm; HRMS calcd. 









carboxamide (30) was prepared according to general procedure (Configuration II) from (R)-benzyl 
2-methylpiperazine-1-carboxylate (116.6 mg, 0.498 mmol), 1-(bromomethyl)-3-(4-(tert-
butyl)phenoxy)benzene (162.3 mg, 0.508 mmol) and 4-chlorobenzyl isocyanate (259.8 mg, 1.55 
mmol) to afford the title compound (224.5 mg, 89%): 1H NMR (500 MHz, DMSO) δ 7.39 (d, J = 
8.6 Hz, 2H), 7.35 (d, J = 8.3 Hz, 2H), 7.26 (d, J = 8.1 Hz, 2H), 7.03 (d, J = 6.7 Hz, 2H), 6.95 (d, J = 
8.3 Hz, 3H), 6.89 (d, J = 7.9 Hz, 1H), 4.22 (qd, J = 15.6, 5.7 Hz, 2H), 4.10 (s, 1H), 3.70 (d, J = 12.6 
Hz, 1H), 3.53 (d, J = 13.9 Hz, 1H), 3.34 (d, J = 13.7 Hz, 1H), 2.92 (t, J = 11.3 Hz, 1H), 2.74 (d, J = 
10.6 Hz, 1H), 2.55 (d, J = 11.0 Hz, 1H), 2.01 (dd, J = 10.8, 2.8 Hz, 1H), 1.92 (t, J = 10.2 Hz, 1H), 
1.28 (s, 9H), 1.05 (d, J = 6.5 Hz, 3H) ppm; 13C NMR (126 MHz, DMSO) δ 157.42, 157.04, 153.96, 
145.89, 140.64, 140.24, 130.87, 129.66, 128.80, 127.97, 126.63, 122.86, 118.63, 117.28, 116.69, 
61.22, 56.91, 52.91, 46.12, 42.80, 38.54, 34.00, 31.21, 15.23 ppm; HRMS calcd. for C30H37ClN3O2 










1-Cyclopentyl-3-(1-(3-(2-fluorophenoxy)benzyl)piperidin-4-yl)urea (31) was prepared according 
to general procedure (Configuration II) from benzyl piperidin-4-ylcarbamate∙HCl (135.6 mg, 0.501 
mmol), 1-(3-(bromomethyl)phenoxy)-2-fluorobenzene (149.0 mg, 0.530 mmol) and 
isocyanatocyclopentane (166.9 mg, 1.50 mmol) to afford the title compound (102.6 mg, 50%): 1H 
NMR (500 MHz, CDCl3) δ 7.22 (t, J = 7.8 Hz, 1H), 7.18–7.11 (m, 1H), 7.11–7.05 (m, 2H), 7.04–
9 
 
7.00 (m, J = 8.7, 5.1 Hz, 2H), 6.98 (s, 1H), 6.81 (dd, J = 8.0, 1.3 Hz, 1H), 5.16 (dd, J = 42.4, 7.2 
Hz, 2H), 4.03–3.92 (m, 1H), 3.58 (d, J = 7.6 Hz, 1H), 3.44 (s, 2H), 2.77 (d, J = 11.0 Hz, 2H), 2.09 
(t, J = 10.9 Hz, 2H), 1.97–1.85 (m, 4H), 1.68–1.51 (m, 4H), 1.46–1.30 (m, 4H) ppm; 13C NMR (126 
MHz, CDCl3) δ 157.96 (s), 157.30 (s), 154.30 (d, J = 248.5 Hz), 143.92 (d, J = 11.3 Hz), 140.88 (s), 
129.41 (s), 124.68 (s), 124.63 (s), 123.82 (s), 121.68 (s), 118.06 (s), 117.05 (d, J = 18.1 Hz), 115.81 
(s), 62.68 (s), 52.48 (s), 51.86 (s), 46.99 (s), 33.63 (s), 33.13 (s), 23.78 (s) ppm; HRMS calcd. for 









1-(4-Methylbenzyl)-3-(1-(3-(3-(trifluoromethyl)phenoxy)benzyl)piperidin-4-yl)urea (32) was 
prepared according to general procedure (Configuration II) from benzyl piperidin-4-yl-
carbamate∙HCl (134.9 mg, 0.498 mmol), 1-(bromomethyl)-3-(3-(trifluoromethyl)phenoxy)benzene 
(167.2 mg, 0.505 mmol) and 4-methylbenzyl isocyanate (219.5 mg, 1.49 mmol) to afford the title 
compound (202.3 mg, 82%): 1H NMR (500 MHz, CDCl3) δ 7.40 (t, J = 8.0 Hz, 1H), 7.33–7.24 (m, 
2H), 7.21 (s, 1H), 7.13 (dd, J = 8.2, 1.5 Hz, 1H), 7.10–7.06 (m, J = 7.8 Hz, 3H), 7.05–7.00 (m, J = 
13.5, 6.0 Hz, 3H), 6.88 (dd, J = 8.0, 2.1 Hz, 1H), 5.40 (s, 1H), 5.01 (d, J = 6.8 Hz, 1H), 4.18 (dd, J 
= 13.4, 5.6 Hz, 2H), 3.49 (d, J = 7.5 Hz, 1H), 3.41 (s, 2H), 2.68 (d, J = 10.5 Hz, 2H), 2.27 (s, J = 
3.4 Hz, 3H), 2.00 (t, J = 10.7 Hz, 2H), 1.79 (d, J = 10.5 Hz, 2H), 1.32 (dd, J = 20.3, 10.6 Hz, 2H) 
ppm; 13C NMR (126 MHz, CDCl3) δ 158.86 (s), 158.08 (d, J = 12.7 Hz), 156.17 (s), 141.37 (s), 
136.73 (s), 136.47 (s), 132.21 (d, J = 32.6 Hz), 130.36 (s), 129.82 (s), 129.28 (s), 127.40 (s), 124.87 
(s), 122.73 (s), 121.54 (s), 119.97 (s), 119.56 (d, J = 3.5 Hz), 118.01 (s), 115.15 (d, J = 3.5 Hz), 
62.65 (s), 52.40 (s), 47.20 (s), 44.09 (s), 32.94 (s), 21.11 (s) ppm; HRMS calcd. for C28H31F3N3O2 









4-(3-Phenoxy-benzyl)-piperazine-1-carboxylic acid 4-chloro-benzylamide (33) was prepared 
according to general procedure (Configuration II) from benzyl piperazine-1-carboxylate (112.8 mg, 
0.512 mmol), 1-(bromomethyl)-3-phenoxybenzene (134.6 mg, 0.512 mmol) and 4-chlorobenzyl 
isocyanate (251.8 mg, 1.502 mmol). After collecting the title compound it was stirred with N-2-
(aminoethyl)-1,2-ethanediamine (478.4 mg, 4.637 mmol) for 1 hour at rt, the solvent was 
evaporated under reduced pressure and the product purified by column chromatography using a 
semi-automatic Combiflash system (24 g silica, eluent gradient: Heptane/EtOAc) to afford the title 
compound (164.9 mg, 74%): 1H NMR (600 MHz, CDCl3) δ 7.30 (tt, J = 4.3, 2.1 Hz, 2H), 7.25–7.22 
(m, 3H), 7.18 (d, J = 8.4 Hz, 2H), 7.09–7.06 (m, 1H), 7.03 (d, J = 7.6 Hz, 1H), 7.00–6.96 (m, 3H), 
6.87 (dd, J = 8.1, 2.5 Hz, 1H), 4.97 (t, J = 5.6 Hz, 1H), 4.32 (d, J = 5.7 Hz, 2H), 3.46 (s, 2H), 3.38–
3.28 (m, 4H), 2.41–2.34 (m, 4H) ppm; 13C NMR (151 MHz, CDCl3) δ 157.60, 157.33, 157.25, 
140.03, 138.23, 132.97, 129.82, 129.64, 129.06, 128.72, 123.93, 123.31, 119.47, 118.86, 117.66, 














Transfections and Tissue Culture 
COS-7 cells were grown at 10% CO2 and 37°C in Dulbecco´s modified Eagle´s medium with 
glutamax (Invitrogen, UK) adjusted with 10% fetal bovine serum, 180 units/ml penicillin, and 45 
µg/ml penicillin/streptomycin (PenStrep). Transfection of the COS-7 cells was performed by the 
calcium phosphate precipitation method (1). Briefly, 6 x 106 cells were transfected with 20 µg of 
human CCR8 cDNA (purchased from www.cDNA.org) in addition to 30 µg of the promiscuous 
chimeric G protein, Gαqi4myr, which is recognized as a Gαi-subunit, but transmit a Gαq signal. Thus, 
the presence of this chimeric G protein turns the Gαi signal, the most common pathway for 
endogenous chemokine receptors, into a Gαq signaling pathway (phospholipase C activation 
measured as IP turnover).[1] 
 
Inositol Phosphate Turnover (IP Turnover)  
COS-7 cells were transfected according to the procedure mentioned above. One day after 
transfection, the cells (35.000 cells/well) were incubated for 24h with 0.67 µCi of myo[3H]inositol 
in 0.1 ml of growth medium per well in a 96-well plate. Cells were washed twice in PBS and 
subsequently incubated for 90min in 0.1 ml Hanks´ Balanced Salt Solution (Invitrogen, UK) 
supplemented with 10 mM LiCl at 37 °C in the presence of various concentrations of ligands. Cells 
were extracted by addition of 50 μl of 10 mM formic acid to each well followed by incubation on 
ice for 30 min. 20µl of the extract were transferred to a white 96-well plate and 80 µl of 1:8 diluted 
YSi Poly-D-lysine coated beads (Perkin Elmer, MA, USA) were added. The plates were sealed and 
shaked at maximum speed for at least 30 min, centrifuged for 5 min at 1500 rpm and γ-radiation 
was counted in a Packard Top Count NXT counter. Determinations were made in duplicates. This 
general functional read-out has previously been used with success in other chemokine receptors.[2] 
 
 
[1]  a) Rosenkilde, M. M., Cahir, M., Gether, U., Hjorth, S. A., Schwartz, T. W., J. Biol. Chem., 
1994, 269, 28160; b) Kostenis, E., Zeng, F. Y., Wess, J., J. Biol. Chem. 1998, 273, 17886 
[2]  a) Jensen, P. C., Thiele, S., Ulven, T., Schwartz, T. W., Rosenkilde, M. M., J. Biol. Chem., 
2008, 283, 23121; b) Thiele, S., Steen, A., Jensen, P. C., Mokrosinski, J., Frimurer, T. M., 
Rosenkilde, M. M., J. Biol. Chem., 2011, 286, 37543 
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